Selective Estrogen Receptor Modulators (SERMs) - A Potential New Treatment for women of child-bearing age with Psychotic Symptoms of Schizophrenia

选择性雌激素受体调节剂（SERM）——一种治疗患有精神分裂症精神病症状的育龄妇女的潜在新疗法

• 批准号: nhmrc : 1007762
• 负责人: Dr Caroline Gurvich
• 金额: $ 14.03万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2011
• 资助国家: 澳大利亚
• 起止时间: 2011-01-01 至 2013-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/selective-estrogen-receptor-symptoms-schizophrenia/109249
• 关键词: Selective; Estrogen; Receptor; Modulators; SERMs

Schizophrenia is a devastating illness urgently requiring a new treatment approach. We have discovered that estrogen is an effective treatment for women with schizophrenia and are currently trialling a safer Selective Estrogen Receptor Modulator (SERM) known as brain estrogen� in postmenopausal women with schizophrenia. Regulatory permission is now available to trial the SERM in younger women, and we seek to extend our current SERM study into child bearing age women with schizophrenia.

精神分裂症是一种毁灭性的疾病，迫切需要新的治疗方法。我们已经发现雌激素对女性精神分裂症患者是一种有效的治疗方法，目前正在对绝经后精神分裂症女性患者试验一种更安全的选择性雌激素受体调节剂（SERM），即脑雌激素。监管部门现已批准在年轻女性中试验SERM，我们寻求将目前的SERM研究扩展到患有精神分裂症的育龄女性。